Lindbrook Capital, LLC Keros Therapeutics, Inc. Transaction History
Lindbrook Capital, LLC
- $1.18 Billion
- Q3 2024
A detailed history of Lindbrook Capital, LLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 113 shares of KROS stock, worth $7,757. This represents 0.0% of its overall portfolio holdings.
Number of Shares
113
Previous 89
26.97%
Holding current value
$7,757
Previous $4,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding KROS
# of Institutions
174Shares Held
30.3MCall Options Held
76.8KPut Options Held
9K-
Black Rock Inc. New York, NY2.51MShares$173 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.9MShares$130 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$127 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.52MShares$105 Million7.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.51MShares$104 Million0.01% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.77B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...